PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12601049-0 2003 Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Budesonide 69-79 vascular endothelial growth factor A Homo sapiens 120-124 32913546-12 2020 Budesonide treatment also resulted in increased HDAC2 expression and decreased IL-8 and VEGF expression. Budesonide 0-10 vascular endothelial growth factor A Homo sapiens 88-92 20359293-0 2010 Effect of budesonide on TGF-beta1-enhanced VEGF production by lung fibroblasts. Budesonide 10-20 vascular endothelial growth factor A Homo sapiens 43-47 20359293-2 2010 Since the glucocorticoids have shown antifibrosis properties, we sought to investigate whether budesonide, a widely used glucocorticoid in clinical practice, could attenuate TGF-beta1 (transforming growth factor-beta1)-induced VEGF production by HFL-1 (human lung fibroblasts). Budesonide 95-105 vascular endothelial growth factor A Homo sapiens 227-231 20359293-6 2010 The results suggested that budesonide pretreatment reduced the significant increase of VEGF release induced by TGF-beta1 in HFL-1 fibroblasts in a dose-dependent manner, and suppressed the increase of phospho-Smad3 and phosphor-ERK (extracellular signal-regulated kinase) protein levels. Budesonide 27-37 vascular endothelial growth factor A Homo sapiens 87-91 20359293-7 2010 In conclusion, budesonide may reduce TGF-beta1-induced VEGF production in the lung, probably through the Smad/ERK signalling pathway and, thus, may provide new sight into the molecular mechanism underlying glucocorticoid therapy for airway inflammatory diseases. Budesonide 15-25 vascular endothelial growth factor A Homo sapiens 55-59 15028972-4 2004 Therefore, we investigated the expression of vascular endothelial growth factor in the colonic mucosa of patients with collagenous colitis before and after long-term treatment with oral budesonide. Budesonide 186-196 vascular endothelial growth factor A Homo sapiens 45-79 15028972-8 2004 After long-term treatment with oral budesonide, the amount of immunostaining for leucocyte-derived vascular endothelial growth factor within the lamina propria decreased significantly to normal levels. Budesonide 36-46 vascular endothelial growth factor A Homo sapiens 99-133 12601049-10 2003 CONCLUSIONS: Budesonide is capable of inhibiting VEGF expression through glucocorticoid receptor activity. Budesonide 13-23 vascular endothelial growth factor A Homo sapiens 49-53 18421428-0 2008 Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma. Budesonide 0-10 vascular endothelial growth factor A Homo sapiens 46-80 18421428-0 2008 Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma. Budesonide 0-10 vascular endothelial growth factor A Homo sapiens 82-86 18421428-0 2008 Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma. Budesonide 0-10 vascular endothelial growth factor A Homo sapiens 92-96 18421428-5 2008 We also investigated the effect of treatment with budesonide/formoterol (Symbicort; AstraZeneca, Lund, Sweden) in the relationship between VEGF and airway remodelling. Budesonide 50-60 vascular endothelial growth factor A Homo sapiens 139-143 18421428-13 2008 After treatment with budesonide/formoterol for 6 months, the expression of VEGF and VEGFR1 was decreased, with correlatory decreased airway remodelling in patients with asthma. Budesonide 21-31 vascular endothelial growth factor A Homo sapiens 75-79 18421428-15 2008 Budesonide/formoterol therapy for 6 months can decrease the expression of VEGF and VEGFR(1) alongside airway remodelling in asthma. Budesonide 0-10 vascular endothelial growth factor A Homo sapiens 74-78 12789234-11 2003 Production of VEGF stimulated by all cytokines was inhibited by budesonide. Budesonide 64-74 vascular endothelial growth factor A Homo sapiens 14-18 12601049-1 2003 PURPOSE: The purpose of this study was to determine whether budesonide inhibits expression of vascular endothelial growth factor (VEGF) in a retinal pigment epithelial cell line (ARPE-19) and to determine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug levels. Budesonide 60-70 vascular endothelial growth factor A Homo sapiens 94-128 12601049-1 2003 PURPOSE: The purpose of this study was to determine whether budesonide inhibits expression of vascular endothelial growth factor (VEGF) in a retinal pigment epithelial cell line (ARPE-19) and to determine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug levels. Budesonide 60-70 vascular endothelial growth factor A Homo sapiens 130-134 12601049-6 2003 RESULTS: At concentrations devoid of cytotoxicity, budesonide inhibited VEGF secretion as well as mRNA expression in ARPE-19 cells in a dose-dependent manner. Budesonide 51-61 vascular endothelial growth factor A Homo sapiens 72-76 12601049-7 2003 RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression. Budesonide 26-36 vascular endothelial growth factor A Homo sapiens 60-64 12601049-7 2003 RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression. Budesonide 26-36 vascular endothelial growth factor A Homo sapiens 79-83 11502275-0 2001 Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Budesonide 0-10 vascular endothelial growth factor A Homo sapiens 19-53 11502275-1 2001 Vascular endothelial growth factor (VEGF), a cytokine expressed in the respiratory epithelial cells, induces vascular hyperpermeability and edema, symptoms that are alleviated by budesonide, an anti-asthma corticosteroid. Budesonide 179-189 vascular endothelial growth factor A Homo sapiens 0-34 11502275-1 2001 Vascular endothelial growth factor (VEGF), a cytokine expressed in the respiratory epithelial cells, induces vascular hyperpermeability and edema, symptoms that are alleviated by budesonide, an anti-asthma corticosteroid. Budesonide 179-189 vascular endothelial growth factor A Homo sapiens 36-40 11502275-2 2001 However, modulation of VEGF levels by budesonide in the respiratory epithelium has not been studied. Budesonide 38-48 vascular endothelial growth factor A Homo sapiens 23-27 11502275-5 2001 At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action. Budesonide 42-52 vascular endothelial growth factor A Homo sapiens 61-65 11502275-5 2001 At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action. Budesonide 42-52 vascular endothelial growth factor A Homo sapiens 80-84 11502275-5 2001 At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action. Budesonide 42-52 vascular endothelial growth factor A Homo sapiens 80-84 11502275-6 2001 Also, budesonide-mediated inhibition of VEGF mRNA was time- and protein synthesis-dependent. Budesonide 6-16 vascular endothelial growth factor A Homo sapiens 40-44 11502275-7 2001 Thus, budesonide may be of potential value in treating disorders of the respiratory tract that are associated with VEGF elevation. Budesonide 6-16 vascular endothelial growth factor A Homo sapiens 115-119